RxDoctor Payments Data

Terence Moraczewski, MD

Family Medicine · Alpharetta, GANPI 1841273422

Payments from drug & device makers

$5,989in general payments, 2019–2025

Across 268 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$683
  • AbbVie$649
  • Amgen$464
  • AstraZeneca$384
  • Astellas Pharma US Inc$239
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,989100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,989 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$307,995
Medicare patients
530
Services billed
6,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide24$22,391
JardianceEmpagliflozin19$16,233
OzempicSemaglutide16$12,750
JanuviaSitagliptin Phosphate15$9,711
SynthroidLevothyroxine Sodium38$3,866
Levothyroxine Sodium210$1,899
Atorvastatin Calcium267$1,758
Rosuvastatin Calcium139$1,223
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid65$1,098
Tamsulosin Hcl63$927
Lisinopril145$924
Simvastatin108$923
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide16$719
Zolpidem Tartrate97$707
Diclofenac Sodium44$668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,403$35,14040 claims
Boehringer IngelheimJardiance$33$16,23319 claims
MerckJanuvia$60$9,71115 claims
AbbVieSynthroid$649$3,86638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →